EVENTIDE ASSET MANAGEMENT, LLC
Q2 2020 13F-HR Holdings
Net value change ($000)
+1,512,167
(49.0%)
New positions
23
Sold out positions
10
Turnover %
11.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| PLRX | 88,412 | NEW |
| W | 82,610 | 269.8% |
| EXAS | 70,540 | 87.4% |
| Biohaven Pharmaceutical Holding Co Ltd. | 69,710 | 114.8% |
| TTD | 64,050 | 110.6% |
| SRPT | 62,270 | 63.9% |
| ASND | 61,602 | 32.2% |
| CRWD | 44,030 | 80.1% |
| ZNTL | 42,496 | NEW |
| TT | 40,364 | 2468.7% |
Top Reduces (Value $000, Stocks/ETFs)
| XYL | -51,648 | -100.0% |
| ZOGENIX, INC. | -37,548 | -53.4% |
| VRNS | -26,741 | -100.0% |
| Sage Therapeutics, Inc. | -22,689 | -100.0% |
| STEMLINE THERAPEUTICS INC | -20,137 | -100.0% |
| CTAS | -19,227 | -100.0% |
| ARYA SCIENCES ACQUISITION CO | -9,032 | -100.0% |
| Myovant Sciences Ltd. | -6,040 | -100.0% |
| Aimmune Therapeutics, Inc. | -2,174 | -3.9% |
| Orchard Therapeutics plc | -2,033 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
137,700
(3.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|